Latest News from C4 Imaging
February 3, 2026
Instead of just localization for radiation, NOVA can be utilized as a precise tumor marker at the time of biopsy.
January 29, 2026
Looking at the Flame trial and the Mirage trial. Delivering higher doses – shorter number of fractions.
January 28, 2026
Without an MRI, when using CT we’re over-contouring the prostate by about 30% on average. NOVA markers, along with CT MR fusion, allow for unmatched precision in treatment planning.
January 27, 2026
Fiducials moved to Carbon because gold fiducials cause dose deflection, but that just caused image modality blindness; NOVA solves both of those problems.
January 26, 2026
Focal Therapy isn’t really “focal” without the NOVA markers. With the NOVA markers, focal therapy can be considered for mass adoption furthering the options for patient treatments.
January 23, 2026
MRI is quickly becoming the standard for treatment planning, and NOVA is the only MRI positive signal fiducial marker on the market.
January 22, 2026
We owe it to our patients, and we owe it to society to use the technology available to us to reduce side effects from toxicity.
January 21, 2026
As Proton Therapy becomes more commonly used and dose perturbation becomes more and more a concern, NOVA provides the confidence needed to accelerate those treatment options.
January 20, 2026
NOVA is the only fiducial marker on the market that can be seen on all image modalities. Imagine a marker that gives all people throughout the cycle of care the same information and how that alone would improve patient care, that’s NOVA.
January 19, 2026
Let’s talk about fiducial markers already on the market, where they fall short. NOVA’s technology is now available to raise the bar in precision.
June 9, 2022
Join me by following C4 Imaging here on LinkedIn – and let’s build a community of champions for innovation on a mission for better patient care.
June 9, 2022
A round table featuring Dr. Peter Orio, Dr. Shalin Shah and our founder, Dr. Steven Frank.
June 9, 2022
MRI Assisted Radiosurgery (MARS) Utilizing C4 Imaging’sSirius ® Positive-Signal MRI Markers.
May 31, 2022
C4 Imaging Announces First Prostate Cancer Treatments Utilizing Nova™ Fiducial Markers.
May 31, 2022
C4 Imaging Announces Addition to Board of Directors.
February 16, 2022
C4 Imaging Announces First Cancer Treatment Utilizing Orion HDR MRI Markers In New Mexico.
February 11, 2021
C4 Imaging Announces Successful Completion of an Institutional Financing Round.
January 5, 2021
C4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Cesium-131 Brachytherapy Seeds
October 26, 2020
C4 Imaging Announces FDA 510(k) Clearance of its Non-metallic, Multimodality C4 Fiducial Marker
September 11, 2019
C4 Imaging Announces First Prostate Cancer Treatment Utilizing Orion™ HDR MRI Markers
September 12, 2018
Theragenics to Provide Sales and Marketing for C4 Imaging’s New Orion™ HDR MRI Markers
May 8, 2018
C4 Imaging Announces FDA 510(k) Clearance of its Positive-Signal High Dose Rate (HDR) Brachytherapy MRI Treatment Planning Marker
September 5, 2017
C4 Imaging Announces an Additional FDA 510(k) Clearance for its Positive-Signal MRI Marker – Sirius™
August 7, 2017
MRI Assisted Radiosurgery (MARS) Utilizing C4 Imaging’s Sirius™ Positive-Signal MRI Marker is a Cost-Effective Option for the Treatment of Prostate Cancer
December 22, 2016
C4 Imaging to Present at the Medtech Showcase 2017 (PDF)
July 5, 2016
Clinical Study Discusses the Value of C4 Imaging’s Sirius™ Positive-Signal MRI Marker in MRI-Guided Prostate Cancer Treatment (PDF)
Jun 6, 2016
C4 Imaging receives top honors at the 5th annual Texas Life Science Forum (PDF)
September 22, 2015
C4 Imaging Utilizes Evonik’s VESTAKEEP® PEEK For Prostate Cancer Device (PDF)
August 21, 2015
C4 Imaging Awarded $1.3 Million NIH SBIR Phase II Grant (PDF)
April 7, 2014
C4 Imaging Announces First SIRIUS™ Positive Signal MRI Marker Implant (PDF)
March 31, 2014
C4 Imaging Signs SIRIUS™ MRI MARKER Loading Services Agreement with AnazaoHealth Corporation (PDF)
Dec 6, 2013
C4 Imaging Announces FDA 510(k) Clearance of its Positive-Signal MRI Marker – Sirius™ (PDF)